606 related articles for article (PubMed ID: 34301253)
1. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.
Quagliariello V; Canale ML; Bisceglia I; Iovine M; Paccone A; Maurea C; Scherillo M; Merola A; Giordano V; Palma G; Luciano A; Bruzzese F; Zito Marino F; Montella M; Franco R; Berretta M; Gabrielli D; Gallucci G; Maurea N
Front Cardiovasc Med; 2024; 11():1289663. PubMed ID: 38818214
[TBL] [Abstract][Full Text] [Related]
4. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.
Barış VÖ; Dinçsoy AB; Gedikli E; Zırh S; Müftüoğlu S; Erdem A
Cardiovasc Toxicol; 2021 Sep; 21(9):747-758. PubMed ID: 34089496
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
7. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
9. Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity.
Wei S; Ma W; Li X; Jiang C; Sun T; Li Y; Zhang B; Li W
Cardiovasc Toxicol; 2020 Oct; 20(5):507-519. PubMed ID: 32607760
[TBL] [Abstract][Full Text] [Related]
10. Combination of
Quagliariello V; Basilicata MG; Pepe G; De Anseris R; Di Mauro A; Scognamiglio G; Palma G; Vestuto V; Buccolo S; Luciano A; Barbieri M; Bruzzese F; Maurea C; Pumpo R; Ostacolo C; Campiglia P; Berretta M; Maurea N
J Cardiovasc Dev Dis; 2022 Nov; 9(12):. PubMed ID: 36547420
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
12. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells.
Quagliariello V; De Laurentiis M; Cocco S; Rea G; Bonelli A; Caronna A; Lombari MC; Conforti G; Berretta M; Botti G; Maurea N
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096896
[TBL] [Abstract][Full Text] [Related]
13. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
[TBL] [Abstract][Full Text] [Related]
15. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
16. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
[TBL] [Abstract][Full Text] [Related]
17. The combination of ursolic acid and empagliflozin relieves diabetic nephropathy by reducing inflammation, oxidative stress and renal fibrosis.
Wu X; Li H; Wan Z; Wang R; Liu J; Liu Q; Zhao H; Wang Z; Zhang H; Guo H; Qi C; Jiao X; Li X
Biomed Pharmacother; 2021 Dec; 144():112267. PubMed ID: 34624679
[TBL] [Abstract][Full Text] [Related]
18. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway.
Zhang J; Huang L; Shi X; Yang L; Hua F; Ma J; Zhu W; Liu X; Xuan R; Shen Y; Liu J; Lai X; Yu P
Aging (Albany NY); 2020 Nov; 12(23):24270-24287. PubMed ID: 33232283
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.
Li XX; Chen ZD; Sun XJ; Yang YQ; Jin H; Liu NF
Acta Pharmacol Sin; 2024 Apr; 45(4):751-764. PubMed ID: 38172306
[TBL] [Abstract][Full Text] [Related]
20. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.
Sukhanov S; Higashi Y; Yoshida T; Mummidi S; Aroor AR; Jeffrey Russell J; Bender SB; DeMarco VG; Chandrasekar B
Cell Signal; 2021 Jan; 77():109825. PubMed ID: 33160017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
